Increased urinary cystatin C indicated higher risk of cardiovascular death in a community cohort

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 108-113

  Helmersson Karlqvist, Johanna ^a   Ärnlöv, Johan ^a,b   Carlsson, Axel C ^a,c   Härmä, Johan ^a   Larsson, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DALARNA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atherosclerosis; Chronic kidney disease; Cr; Epidemiology; HR; Mortality; Risk factors; U Alb; U CysC; U KIM 1; U NGAL

Indexed keywords

BIOLOGICAL MARKER; CYSTATIN C;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HEALTH SURVEY; HUMAN; INCIDENCE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; CARDIOVASCULAR DISEASE; DEMOGRAPHY; MORTALITY; RISK ASSESSMENT; RISK FACTOR; TIME; URINE;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYSTATIN C; FOLLOW-UP STUDIES; HUMANS; MALE; RESIDENCE CHARACTERISTICS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84897951251     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.020     Document Type: Article

References (45)

1. Grubb A., Löfberg H. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci U S A 1982, 79:3024-3027.
2. Turk B., Turk V., Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997, 378:141-150.
3. Finney H., Newman D.J., Price C.P. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000, 37(Pt 1):49-59.
4. Galteau M.M., Guyon M., Gueguen R., Siest G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001, 39:850-857.
5. Grubb A.O. Cystatin C - properties and use as diagnostic marker. Adv Clin Chem 2000, 35:63-99.
6. Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem 2002, 48:699-707.
7. Larsson A., Malm J., Grubb A., Hansson L.O. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004, 64:25-30.
8. Jacobsson B., Lignelid H., Bergerheim U.S. Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 1995, 26:559-564.
9. Uchida K., Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002, 323:121-128.
10. Hikmet Noraddin F., Flodin M., Fredricsson A., Sohrabian A., Larsson A. Measurement of urinary cystatin C with a particle-enhanced turbidimetric immunoassay on Architect Ci8200. JClin Lab Anal 2012, 26:358-364.
11. Sohrabian A., Noraddin F.H., Flodin M., Fredricsson A., Larsson A. Particle enhanced turbidimetric immunoassay for the determination of urine cystatin C on Cobas c501. Clin Biochem 2012, 45:339-344.
12. Conti M., Moutereau S., Zater M., et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 2006, 44:288-291.
13. Herget-Rosenthal S., van Wijk J.A., Brocker-Preuss M., Bokenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem 2007, 40:946-951.
14. Koyner J.L., Bennett M.R., Worcester E.M., et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008, 74:1059-1069.
15. Koyner J.L., Vaidya V.S., Bennett M.R., et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010, 5:2154-2165.
16. Nejat M., Pickering J.W., Walker R.J., et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care 2010, 14:R85.
17. Hall I.E., Koyner J.L., Doshi M.D., Marcus R.J., Parikh C.R. Urine cystatin C as a biomarker of proximal tubular function immediately after kidney transplantation. Am J Nephrol 2011, 33:407-413.
18. Zhang Z., Lu B., Sheng X., Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis 2011, 58:356-365.
19. Endre Z.H., Pickering J.W., Walker R.J., et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011, 79:1119-1130.
20. Li Y., Fu C., Zhou X., et al. Urine interleukin-18 and cystatin-C as biomarkers of acute kidney injury in critically ill neonates. Pediatr Nephrol 2012, 27:851-860.
21. Lock E.A. Sensitive and early markers of renal injury: where are we and what is the way forward?. Toxicol Sci 2010, 116:1-4.
22. Ärnlöv J. Diminished renal function and the incidence of heart failure. Curr Cardiol Rev 2009, 5:223-227.
23. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
24. Nerpin E., Ingelsson E., Riserus U., et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant 2011, 26:2820-2827.
25. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. NEngl J Med 2005, 352:2049-2060.
26. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
27. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
28. Byberg L., Siegbahn A., Berglund L., McKeigue P., Reneland R., Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 1998, 18:258-264.
29. Helmersson J., Vessby B., Larsson A., Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004, 109:1729-1734.
30. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. NEngl J Med 2008, 358:2107-2116.
31. Larsson A., Helmersson J., Hansson L.O., Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 2005, 65:301-305.
32. Phillips A.O. The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep 2003, 3:491-496.
33. Weitgasser R., Schnoell F., Gappmayer B., Kartnig I. Prospective evaluation of urinary N-acetyl-beta-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 1999, 22:1882-1886.
34. Yoshikawa R., Wada J., Seiki K., et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 76:358-367.
35. Helmersson-Karlqvist J., Larsson A., Carlsson A.C., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in a community-based cohort of older Swedish men. Atherosclerosis 2013, 227:408-413.
36. Carlsson A.C., Larsson A., Helmersson-Karlqvist J., et al. Urinary kidney injury molecule 1 and incidence of heart failure in elderly men. Eur J Heart Fail 2013, 15:441-446.
37. Haraldsson B., Nyström J., Deen W.M. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008, 88:451-487.
38. Comper W.D., Russo L.M. The glomerular filter: an imperfect barrier is required for perfect renal function. Curr Opin Nephrol Hypertens 2009, 18:336-342.
39. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989, 32:219-226.
40. de Zeeuw D., Parving H.H., Henning R.H. Microalbuminuria as an early marker for cardiovascular disease. JAm Soc Nephrol 2006, 17:2100-2105.
41. Esposito K., Nappo F., Marfella R., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
42. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
43. Rifkin D.E., Shlipak M.G., Katz R., et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008, 168:2212-2218.
44. Florvall G., Basu S., Helmersson J., Larsson A. Microalbuminuria measured by three different methods, blood pressure and cardiovascular risk factors in elderly Swedish males. Anal Chem Insights 2008, 3:69-74.
45. Almgren T., Wilhelmsen L., Samuelsson O., Himmelmann A., Rosengren A., Andersson O.K. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. JHypertens 2007, 25:1311-1317.